margetuximab
Commercial- Indications
- Metastatic HER2-positive breast cancer
Company intelligence / Profile preview
TerSera Therapeutics commercializes and develops specialty pharmaceuticals focused on oncology, acute care, non-opioid pain management, and rare diseases. Its portfolio includes several FDA-approved drugs such as Zoladex® for hormone-sensitive cancers, Xermelo® for carcinoid syndrome diarrhea, Quzyttir™ injection to prevent infusion reactions, and the soon-to-be-acquired MARGENZA® monoclonal antibody for metastatic HER2+ breast cancer.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on TerSera Therapeutics.